Search Results - "Sicignano G"

EP-1347: Hypofractionated whole brain irradiation with hippocampal sparing and SIB for metastases: a dosimetric VMAT study.

Authors: Sicignano, G. Giaj Levra, N. Fiorentino, A. et al.

Source: Radiotherapy & Oncology. 2014 Supplement, Vol. 115, pS726-S726. 1p.

Subjects: Dose fractionation, Metastasis, Treatment of brain cancer, Medical dosimetry, Cancer radiotherapy

PO-0705: IGRT tracking prostate fiducials increases risk of acute diarrhea during whole pelvis IMRT/VMAT for prostate cancer.

Authors: Sicignano, G. Ricchetti, F. Proto, T. et al.

Source: Radiotherapy & Oncology. Mar2013 Supplement 2, Vol. 106, pS270-S270. 1p.

Subjects: Prostate cancer treatment, Image-guided radiation therapy, Diarrhea, Fiducial markers (Imaging systems), Cancer radiotherapy complications, Intensity modulated radiotherapy, Volumetric analysis

FACTORS ASSOCIATED WITH PITUITARY FUNCTION AFTER GAMMA KNIFE RADIOSURGERY (GKS) OF PITUITARY ADENOMAS

Authors: Sicignano, G. Losa, M. Cattaneo, G.M. et al.

Source: Radiotherapy & Oncology. Mar2011 Supplement 2, Vol. 98, pS38-S38. 1p.

PO-1452 Stereotactic ablative radiotherapy in patients with refractory ventricular tachyarrhythmia.

Authors: Nicosia, L. Giaj-Levra, N. Sicignano, G. et al.

Source: Radiotherapy & Oncology. 2022 Supplement 1, Vol. 170, pS1232-S1233. 2p.

Subjects: Ventricular tachycardia, Stereotactic radiotherapy, Refractory materials

EP-1103: Are hippocampi considered organs at risks during stereotactic radiotherapy for brain metastases?

Authors: Tebano, U. Fiorentino, A. Sicignano, G. et al.

Source: Radiotherapy & Oncology. May2017 Supplement 1, Vol. 123, pS604-S605. 1p.

EP-1104: SABR for brain metastases with VMAT and FFF: feasibility and early clinical results.

Authors: Giaj Levra, N. Fiorentino, A. Sicignano, G. et al.

Source: Radiotherapy & Oncology. May2017 Supplement 1, Vol. 123, pS605-S605. 1p.

PO-1485 1.5T MR-guided daily adaptive radiotherapy: preliminary clinical report of the first 5000 fractions.

Authors: Rigo, M. Giaj-Levra, N. Mazzola, R. et al.

Source: Radiotherapy & Oncology. 2023 Supplement 1, Vol. 182, pS1203-S1204. 2p.

EP-1683: Left breast IMRT with SIB: a user improved technique to reduce heart and lung dose.

Authors: Naccarato, S. Ruggieri, R. Sicignano, G. et al.

Source: Radiotherapy & Oncology. Apr2016 Supplement 1, Vol. 119, pS786-S786. 1p.

Subjects: Breast cancer treatment, Intensity modulated radiotherapy, Cancer radiotherapy, Cancer research, Medical technologists, Medical publishing

Intensity modulated radiation therapy with simultaneous integrated boost in early breast cancer irradiation. Report of feasibility and preliminary toxicity.

Authors: Fiorentino, A. Mazzola, R. Ricchetti, F. et al.

Source: Cancer Radiothérapie. Aug2015, Vol. 19 Issue 5, p289-294. 6p.

Adaptive Replanning After 5 Treatment Fractions in Prostate Patients With Implanted Markers Impacts on Setup Accuracy.

Authors: Ruggieri, R. Naccarato, S. Sicignano, G. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. Oct2013 Supplement, Vol. 87, pS680-S680. 1p.

Subjects: Prostate cancer patients, Biomarkers, Artificial implants, Cancer radiotherapy, Medical research

Dose-volume-related dysphagia after constrictor muscles definition in head and neck cancer intensity-modulated radiation treatment.

Authors: MAZZOLA, R. RICCHETTI, F. FIORENTINO, A. et al.

Source: British Journal of Radiology. Dec2014, Vol. 87 Issue 1044, p1-10. 10p.

PD-0575 Toxicity and QoL report of 1.5T MR-guided SBRT for prostate cancer in the first 100 patients.

Authors: Cuccia, F. Figlia, V. Rigo, M. et al.

Source: Radiotherapy & Oncology. 2022 Supplement 1, Vol. 170, pS503-S504. 2p.

PO-1512 Daily adaptive MR-guided SBRT for oligometastatic lymph-nodes:feasibility and preliminary experience.

Authors: Rigo, M. Cuccia, F. Figlia, V. et al.

Source: Radiotherapy & Oncology. 2021 Supplement 1, Vol. 161, pS1239-S1240. 2p.

PO-1388 1.5 T MR-guided SBRT for oligorecurrent prostate cancer: preliminary report of feasibility and PROMs.

Authors: Cuccia, F. Mazzola, R. Figlia, V. et al.

Source: Radiotherapy & Oncology. 2021 Supplement 1, Vol. 161, pS1138-S1139. 2p.

PO-1486 Feasibility and tolerability of MR-guided adaptive RT on prostatic bed:mono-institutional experience.

Authors: RIGO, M. Giaj-Levra, N. Mazzola, R. et al.

Source: Radiotherapy & Oncology. 2023 Supplement 1, Vol. 182, pS1204-S1204. 1p.

Preliminary Dosimetric Analysis of the First 150 Sessions of 1.5-T MR-Guided Daily-Adaptive Radiotherapy for Abdomino-Pelvic Lymph-Nodal Oligometastases.

Authors: Cuccia, F. Rigo, M. Gurrera, D. et al.

Source: International Journal of Radiation Oncology, Biology, Physics. 2021 Supplement, Vol. 111 Issue 3, pe551-e551. 1p.

PO-1499 1.5T MR-guided daily adaptive radiotherapy: preliminary clinical report of the first 2000 fractions.

Authors: Rigo, M. Cuccia, F. Figlia, V. et al.

Source: Radiotherapy & Oncology. 2021 Supplement 1, Vol. 161, pS1228-S1228. 1p.

PO-1439 Clinical results of SBRT for spinal metastases using dedicated contouring/planning system.

Authors: Figlia, V. Giaj-Levra, N. Mazzola, R. et al.

Source: Radiotherapy & Oncology. 2021 Supplement 1, Vol. 161, pS1181-S1181. 1p.

EP-1558 Updated results of a Phase II study on 5 fractions FFF SBRT for low and intermediate prostate cancer.

Authors: Alongi, F. Nicosia, L. Mazzola, R. et al.

Source: Radiotherapy & Oncology. 2019 Supplement 1, Vol. 133, pS841-S842. 2p.

PO-0929: Mammary chain irradiation: can we reduce the risk of secondary cancer and ischaemic heart disease?

Authors: Corradini, S. Figlia, V. Simonetto, C. et al.

Source: Radiotherapy & Oncology. 2020 Supplement 1, Vol. 152, pS496-S496. 1p.